MedTrace Logo

Oral DS107 in Moderate to Severe Atopic Dermatitis

NCT02211417 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2022-10-07

Study results available
· View outcomes & findings →

Summary

This study will compare the safety and efficacy of Oral DS107 (2 g) to placebo in patients with moderate to severe atopic dermatitis.

Oral DS107 (2 g) will be orally administered for 8 weeks, and will be compared against placebo.

This study will enroll approximately 100 adult patients.

Conditions

Interventions

DRUG

Oral DS107

DRUG

Placebo

Sponsors & Collaborators

  • Dignity Sciences Ltd.

    lead INDUSTRY

Principal Investigators

  • John Climax, Ph.D. · Dignity Sciences Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2015-11-30
Completion
2015-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02211417 on ClinicalTrials.gov